ASLAN PHARMACEUTICALS TO PRESENT AT 9th ANNUAL SVB LEERINK GLOBAL HEALTHCARE CONFERENCE

Singapore, 24 February 2020 – ASLAN Pharmaceuticals Limited (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company, today announced its presentation at the 9^th Annual SVB Leerink Global Healthcare Conference. Dr Carl Firth, Chief Executive Officer, and Stephen Doyle, Chief Business Officer, is scheduled to present an overview of the company on Wednesday, 26 February 2020 at 09:00am EST. The conference will be held from 25-27 February 2020 in New York.

An archived version of the presentation will be available in the Investors section of ASLAN’s website at www.aslanpharma.com following the event.

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497) is a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative product candidates that target significant unmet medical needs and global market opportunities. Led by a senior management team with extensive experience in global development and commercialisation, ASLAN has a clinical portfolio comprised of a first in class monoclonal therapy, ASLAN004, that is being developed in atopic dermatitis and other immunology indications, and a small molecule inhibitor targeting oncology. ASLAN’s partners include Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL. For additional information please visit www.aslanpharma.com.